Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094695 | 0.84 | HTR2A (0.47) | ESR1ESR2KDM1ADRD1MAPK1 | |
| SCHEMBL1095022 | 0.84 | ESR1 (0.45) | ESR1ESR2DRD1THPOHSD17B10 | |
| SCHEMBL1095978 | 0.84 | ESR1 (0.42) | ESR1ESR2KDM1AMAOADRD1 | |
| SCHEMBL12110142 | 0.83 | MAOA (0.35) | MAOADRD1MAPK1THPOHIF1A | |
| SCHEMBL2310177 | 0.82 | ESR2 (0.52) | ESR1ESR2ABHD6 | |
| SCHEMBL1294025 | 0.81 | ESR2 (0.46) | ESR2MAOAMAPK1KDM4EMAPT | |
| SCHEMBL23745324 | 0.80 | ESR1 (0.45) | ESR1ESR2DRD1THPOHSD17B10 | |
| SCHEMBL31121185 | 0.80 | ESR1 (0.45) | ESR1ESR2DRD1THPOHSD17B10 | |
| SCHEMBL12110125 | 0.80 | MAOA (0.40) | MAOADRD1MAPK1THPOHIF1A | |
| SCHEMBL4932882 | 0.79 | ESR2 (0.60) | ESR1ESR2DRD1DRD2ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598434-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9598434-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9598434-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-9108977-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108977-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108977-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| EP-2546255-A1 | BENZAZEPINE COMPOUND | Astellas Pharma Inc. (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20130012496-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130012496-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130012496-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012496-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | ESR1 216/4885ESR2 182/4885KDM1A 722/4885 |
| US-20110269744-A1 | Benzazepine Compound | HTR2C, HTR3C, HTR2A | ESR1 205/4885ESR2 185/4885KDM1A 893/4885 |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | ESR1 216/4885ESR2 182/4885KDM1A 722/4885 |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | ESR1 216/4885ESR2 182/4885KDM1A 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.